|
Volumn 30, Issue 1, 2008, Pages 27-45
|
Impacts of a disease management program for dually eligible beneficiaries
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTILIPEMIC AGENT;
BETA ADRENERGIC RECEPTOR BLOCKING AGENT;
DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;
HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;
MISCELLANEOUS DRUGS AND AGENTS;
AGED;
ARTICLE;
CONGESTIVE HEART FAILURE;
CONTROLLED STUDY;
COST EFFECTIVENESS ANALYSIS;
DIABETES MELLITUS;
DRUG UTILIZATION;
FEMALE;
HEALTH CARE COST;
HEALTH CARE MANAGEMENT;
HEALTH CARE SYSTEM;
HEALTH EDUCATION;
HEALTH INSURANCE;
HEALTH PROGRAM;
HUMAN;
ISCHEMIC HEART DISEASE;
MAJOR CLINICAL STUDY;
MALE;
MEDICAID;
MEDICARE;
PATIENT EDUCATION;
POPULATION BASED CASE CONTROL STUDY;
PRESCRIPTION;
QUALITY OF LIFE;
TELEPHONE TELEMETRY;
TREATMENT DURATION;
TREATMENT OUTCOME;
UNITED STATES;
AGED;
AGED, 80 AND OVER;
COST CONTROL;
DISEASE MANAGEMENT;
ELIGIBILITY DETERMINATION;
FEMALE;
FLORIDA;
HEART FAILURE;
HUMANS;
MALE;
MEDICARE;
PROGRAM DEVELOPMENT;
PROGRAM EVALUATION;
UNITED STATES;
|
EID: 55949092880
PISSN: 01958631
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
Times cited : (23)
|
References (6)
|